Gepotidacin

Brand names: Blujepa · Active ingredient: Gepotidacin Mesylate

In short: BLUJEPA is indicated in female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) for the treatment of uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freund

Forms & strengthsEach film coated tablet of BLUJEPA contains 750 mg of gepotidacin. BLUJEPA tablets are yellow, capsule shaped, and debossed with “GS GU3” on one side and plain on the other side.
LabelGlaxoSmithKline LLC
Label updatedFeb 23, 2026

What is Gepotidacin used for?

BLUJEPA is indicated in female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) for the treatment of uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, and Enterococcus faecalis.

BLUJEPA is indicated in adult and pediatric patients 12 years of age and older weighing at least 45 kilograms (kg) who have limited or no alternative options for the treatment of uncomplicated urogenital gonorrhea caused by susceptible strains of Neisseria gonorrhoeae. Approval of this indication is based on limited clinical safety data for BLUJEPA .

To reduce the development of drug-resistant bacteria and maintain the effectiveness of BLUJEPA and other antibacterial drugs, BLUJEPA should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Gepotidacin dosage

The recommended dosage of BLUJEPA is 1,500 mg (two 750 mg tablets) taken orally, twice daily (approximately 12 hours apart) for 5 days in female adult and pediatric patients 12 years of age and older with uncomplicated uUTI .

The recommended dose of BLUJEPA is 3,000 mg (four 750 mg tablets) taken orally, followed by a second dose of 3,000 mg (four 750 mg tablets) approximately 12 hours later in adult and pediatric patients 12 years of age and older weighing at least 45 kg with uncomplicated urogenital gonorrhea .

Do not increase the dose, extend the duration of treatment, or reduce the interval between doses due to the risk of QTc interval prolongation .

Administer BLUJEPA tablets after a meal to reduce the possibility of gastrointestinal intolerance .

If a dose is missed, instruct patients to take the missed dose as soon as possible. For uUTI, do

not

double the dose to make up for a missed dose.

How to take Gepotidacin — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Important Administration Instructions

Counsel patients to take BLUJEPA after a meal to reduce the possibility of gastrointestinal intolerance .

Prolongation of the QTc Interval

Counsel patients to inform their healthcare provider of any personal or family history of QTc prolongation or proarrhythmic conditions such as hypokalemia, bradycardia, or recent myocardial ischemia, or if they are taking any antiarrhythmic agents. Advise patients to notify their healthcare providers if they have any symptoms of prolongation of the QTc interval, including prolonged heart palpitations or a loss of consciousness .

Acetylcholinesterase Inhibition

Counsel patients that BLUJEPA can cause dysarthria and other symptoms such as syncope, presyncope, muscle spasms, diarrhea, nausea, vomiting, abdominal pain, hypersalivation, and hyperhidrosis. …

Warnings & precautions

Do not take this medicine if: BLUJEPA is contraindicated in patients with a history of severe hypersensitivity to BLUJEPA .

A dose and concentration-dependent prolongation of the QTc interval has been observed with BLUJEPA .

Avoid BLUJEPA in patients with a history of QTc interval prolongation or those with relevant pre‑existing cardiac disease, patients taking antiarrhythmic agents, or other medications that may potentially prolong the QTc interval .

Due to an increase in gepotidacin exposure (Cmax), and the risk of QTc interval prolongation, avoid BLUJEPA in patients who have any of the following risk factors :

•

Concomitant use of strong CYP3A4 inhibitors

•

Severe renal impairment (estimated glomerular filtration rate [eGFR] <30 mL/min)

•

Severe hepatic impairment (Child-Pugh Class C)

Additionally, avoid BLUJEPA in uncomplicated urogenital gonorrhea patients who also have any of the following risk factors for increased gepotidacin exposure :

•

Concomitant use of moderate CYP3A4 inhibitors

•

Two or more of the following risk factors:

o

Body weight between 45 kg and 60 kg

o

Moderate renal impairment (eGFR 30 to 59 mL/min)

o

Moderate hepatic impairment (Child‑Pugh Class B)

If administration of BLUJEPA cannot be avoided in these patients, monitor and correct serum electrolyte abnormalities and collect an ECG prior to administration and during treatment, as clinically indicated.

BLUJEPA is a reversible acetylcholinesterase inhibitor in in vitro laboratory studies. Adverse reactions including dysarthria, syncope, presyncope, muscle spasms, diarrhea, nausea, vomiting, abdominal pain, hypersalivation, and hyperhidrosis which are potentially attributed to acetylcholinesterase inhibition, have been observed in clinical trials . …

Gepotidacin side effects

The following adverse reactions are discussed in greater detail in other sections of the labeling:

•QTc Prolongation .

•Acetylcholinesterase Inhibition .

•Hypersensitivity Reactions .

•Clostridioides difficile Infection .

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical Trial Experience in Patients with Uncomplicated UTI

The safety of BLUJEPA was evaluated in 2 double‑blind, active‑controlled, randomized trials in female adult and pediatric patients 12 years of age and older with uUTI (Trial 1 and Trial 2). A total of 1,570 patients were treated with BLUJEPA and 1,558 patients were treated with nitrofurantoin (pooled safety populations for BLUJEPA and nitrofurantoin, respectively). Patients received treatment for a median duration of 5 days.

In Trials 1 and 2 (pooled, intent-to-treat [ITT] population), the median age of patients treated with BLUJEPA was 49 (range 13 to 89) years; <1% were <18 years, 77% of patients were 18 to 64 years, 14% were 65 to 74 years, and 8% were ≥75 years. Patients were female (100%) and White (83%), Black or African American (7%), Asian (5%), or American Indian or Alaskan Native (4%); for ethnicity, 33% identified as Hispanic/Latino and 67% as non-Hispanic/Latino. The majority of patients were enrolled from the U.S. (55%). …

Drug interactions

CYP3A4 Inhibitors

Indication | Moderate CYP3A4 Inhibitors | Strong CYP3A4 Inhibitors

Uncomplicated UTI | No dosage adjustment | Avoid concomitant administration of BLUJEPA with strong inhibitors of CYP3A4 due to an increase in gepotidacin exposure .

Uncomplicated Urogenital Gonorrhea | Avoid concomitant administration of BLUJEPA with moderate CYP3A4 inhibitors due to an increase in gepotidacin exposure . | Avoid concomitant administration of BLUJEPA with strong inhibitors of CYP3A4 due to an increase in gepotidacin exposure .

CYP3A4 Inducers

Due to decreased gepotidacin exposures, avoid coadministration of BLUJEPA with CYP3A4 inducers as follows:

•Uncomplicated urinary tract infections: Avoid concomitant use of BLUJEPA with strong CYP3A4 inducers .

•Uncomplicated urogenital gonorrhea: Avoid concomitant use of BLUJEPA with strong and moderate CYP3A4 inducers .

CYP3A4 Substrates

Avoid concomitant administration of BLUJEPA with drugs that are extensively metabolized by CYP3A4 where minimal concentration changes may lead to serious adverse reactions .

Digoxin

Due to an increase in digoxin exposures, consider monitoring digoxin serum concentrations, as appropriate, with concomitant administration of BLUJEPA . …

About this medicine

BLUJEPA tablets contain gepotidacin mesylate, a triazaacenaphthylene antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV. The chemical name is (R)-2-((4-(((3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-yl)methyl)amino)piperidin-1-yl)methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione methanesulfonate dihydrate. The molecular formula is C24H28N6O3â—ŹCH4O3Sâ—Ź2H2O and its molecular mass is 580.66. The structural formula is shown below.

*stereogenic center

Each BLUJEPA oral tablet contains gepotidacin 750 mg (equivalent to 910.7 mg of gepotidacin mesylate [anhydrous]). Inactive ingredients include colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, and yellow iron oxide.

How it works: BLUJEPA is an antibacterial drug . The 24-hour free‑drug AUC to minimum inhibitory concentration (MIC) ratio has been shown in animal infection and in vitro pharmacokinetic ‑pharmacodynamic (PK‑PD) models to be the PK‑PD index predictive of gepotidacin antibacterial efficacy. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 80b57cfe-7819-4d95-a57d-014af42f118d. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin